-
1.
公开(公告)号:US20230286010A1
公开(公告)日:2023-09-14
申请号:US18020007
申请日:2021-08-05
发明人: Eduardo ROSA-MOLINAR
IPC分类号: B05C1/08 , G01N23/2202 , G01N23/2251
CPC分类号: B05C1/0821 , B05C1/0817 , G01N23/2202 , G01N23/2251
摘要: Disclosed are reel-to-reel coating systems that can be used to form graphene-coated tapes. The coating systems can be modular, self-contained, and sized to allow for benchtop fabrication of coated tape substrates for use in imaging applications. The reels of the coating system can be removable, and adapted to be re-attached to an in-situ scanning electron microscope reel-to-reel imaging system, a reel-to-reel system for sectioning resin-embedded cells and/or tissues with an ultramicrotome, or any combination thereof. In this way, the coater can serve as part of an integrated system facilitating efficient, serial sample processing and imaging.
-
公开(公告)号:US11460356B2
公开(公告)日:2022-10-04
申请号:US16895965
申请日:2020-06-08
发明人: Cory Berkland , Jonathan Whitlow , Jean Salash
IPC分类号: G01L1/12 , C09D11/037 , C09D11/102 , H01F7/20 , B33Y10/00 , B33Y70/00 , B33Y80/00 , B29K509/08 , H01F1/032 , B29C64/118 , B29K83/00 , B29K105/16
摘要: Disclosed are functional materials for use in additive manufacturing (AM). The functional material can comprise an elastomeric composition (e.g., a silicone composite) for use in, for example, direct ink writing. The elastomeric composition can include and elastomeric resin, and a magnetic nanorod filler dispersed within the elastomeric resin. Nanorod characteristics (e.g., length, diameter, aspect ratio) can be selected to create 3D-printed constructs with desired mechanical properties along different axes. Furthermore, since nickel nanorods are ferromagnetic, the spatial distribution and orientation of nanorods within the continuous phase can be controlled with an external magnetic field. This level of control over the nanostructure of the material system offers another degree of freedom in the design of functional parts and components with anisotropic properties. Magnetic fields can be used to remotely sense compression of the constructs, or alternatively, control the stiffness of these materials.
-
公开(公告)号:US20220117847A1
公开(公告)日:2022-04-21
申请号:US17337914
申请日:2021-06-03
发明人: Jesse Drake , Justin McCarthy , David Parrott , Joshua Rose , Patrick T. Thrailkill , Charlotte A. Gallagher , Kate Cutuli , Diana Sulas Thompson , Zachary S. Collins
摘要: An apparatus and methods for embolization of a patient includes vials for containing radiomicrospheres including inclined and domed base are described. Apparatus for delivering the microspheres from the vials to a patient for radioembolization are also described.
-
公开(公告)号:US20210307985A1
公开(公告)日:2021-10-07
申请号:US17219330
申请日:2021-03-31
发明人: Jared STAAB , Brent BARTA , Brigid FLYNN , Tim KRAUSE , Jay NACHTIGAL
摘要: An aerosolization mitigation device is provided. The aerosolization mitigation device can include a negative pressure aerosolization mitigation system. A transparent barrier can form a frame of the system, and a negative pressure can be generated in the internal volume. The device can isolate a patient to allow ambulatory, surgical, and routine care to proceed during periods of higher patient volume or viral transmission. The negative pressure environment mitigates viral transmission to protect healthcare providers and others in the vicinity of the patient from health risks during patient care.
-
公开(公告)号:US20210268121A1
公开(公告)日:2021-09-02
申请号:US17236561
申请日:2021-04-21
发明人: Mei He
IPC分类号: A61K47/69 , G01N33/543 , G01N33/574
摘要: Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.
-
公开(公告)号:US20210018501A1
公开(公告)日:2021-01-21
申请号:US17032037
申请日:2020-09-25
发明人: Peng Zhang , Yong Zeng , Mei He
IPC分类号: G01N33/543 , B01L3/00 , G01N33/68
摘要: A graphene-based sandwich immunoassay for detecting whether a target biological substance is present in a sample, generally comprising contacting said sample with a plurality of particles coated with graphene nanosheets, each particle having at least one targeting receptor, such that the target biological substance, if present, associates with the targeting receptor, and detecting the presence of the target biological substance in the sample by subsequently contacting the sample with a detection antibody, wherein the detection antibody is capable of targeting and binding with the target biological substance if bound to the targeting receptor to yield a detectable complex. The targeting receptor can be an antibody or fragment thereof. The target biological substance can be an exosome.
-
公开(公告)号:US20210008111A1
公开(公告)日:2021-01-14
申请号:US16924950
申请日:2020-07-09
发明人: Amara Seng , Ryan Fischer , Thomas Yankee , Mary Markiewicz , John Szarejko
IPC分类号: A61K35/17 , C12N15/86 , C12N5/0783
摘要: Cell therapy compositions comprising engineered human regulatory T cells (eTregs) characterized by ectopic overexpression of FOXP3 and Helios protein, produced via introduction of separate nucleic acid constructs respectively encoding FOXP3 and Helios (FOXP3+Helios+eTregs). Cell therapy compositions comprising mixed populations of CD4+ and CD8+ Treg cells each with ectopic overexpression of FOXP3 and Helios. Methods of making and use the same for therapies involving inflammation and/or a disorder of the immune system.
-
公开(公告)号:US10663471B2
公开(公告)日:2020-05-26
申请号:US16362280
申请日:2019-03-22
发明人: Blake R. Peterson , Digamber Rane
IPC分类号: G01N33/58 , G01N33/533 , G01N33/50 , C09B57/00
摘要: A compound can be a pro-fluorophore peroxynitrite sensor that generates a fluorophore when cleaved by peroxynitrite, having a structure of Formula A: wherein: moiety A is an ER-targeting fluorophore; Y is a linker; and moiety B is a phenol, substituted or unsubstituted, wherein the structure of Formula A is less fluorescent than the ER-targeting fluorophore moiety A.
-
公开(公告)号:US10335515B2
公开(公告)日:2019-07-02
申请号:US14918229
申请日:2015-10-20
发明人: Michael Detamore , Emily Beck , Stevin Gehrke , Cory Berkland
摘要: An implantable hydrogel precursor composition can include: a cross-linkable polymer matrix that is biocompatible; and a plurality of polymer particles in the cross-linkable polymer matrix. The cross-linkable polymer matrix can include a cross-linkable hyaluronic acid polymer that has cross-linkable functional groups. The hyaluronic acid polymer can be a methacrylated hyaluronic acid polymer. The methacrylated hyaluronic acid polymer can have a molecular weight from about 500 kDa to about 1.8 MDa. The polymer particles can include a cross-linked hyaluronic acid. The cross-linkable polymer matrix having the polymer particles has a yield stress. The cross-linkable polymer matrix having the polymer particles has shape retention at physiological temperatures. The composition can include live cells in the cross-linkable polymer matrix. The composition can include a biologically active agent in the cross-linkable polymer matrix.
-
公开(公告)号:US10246681B2
公开(公告)日:2019-04-02
申请号:US15353244
申请日:2016-11-16
IPC分类号: A61K35/30 , C12N15/113 , C12N5/0793
摘要: A method of transforming human cells into mechanosensory hair cells (MHCs), such as inner hear hair cells in the cochlea and vestibular organs, can include: causing human Wharton's jelly cells (hWJCs) to increase expression of or biological function of HATH1 so as to transform the hWJCs into MHCs. The method can include; administering a nucleic acid that encodes HATH1 to the hWJCs; causing inhibited expression of or biological function of HES1 and/or HES5 in the hWJCs; administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5 to the hWJCs; causing inhibited expression of or biological function of HES1 and/or HES5 in the WJCs by administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5; nucleic acids are administered includes a sequence of SEQ ID NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4.
-
-
-
-
-
-
-
-
-